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Background. Normal subjects deactivate specific brain regions, notably the posteromedial cortex (PMC), during many tasks.
Recent cross-sectional functional magnetic resonance imaging (fMRI) data suggests that deactivation during memory tasks is
impaired in Alzheimer’s disease (AD). The goal of this study was to prospectively determine the prognostic significance of PMC
deactivation in mild cognitive impairment (MCI). Methodology/Principal Findings. 75 subjects (34 MCI, 13 AD subjects and
28 controls) underwent baseline fMRI scanning during encoding of novel and familiar face-name pairs. MCI subjects were
followed longitudinally to determine conversion to AD. Regression and analysis of covariance models were used to assess the
effect of PMC activation/deactivation on conversion to dementia as well as in the longitudinal change in dementia measures.
At longitudinal follow up of up to 3.5 years (mean 2.560.79 years), 11 MCI subjects converted to AD. The proportion of
deactivators was significantly different across all groups: controls (79%), MCI-Nonconverters (73%), MCI-converters (45%), and
AD (23%) (p,0.05). Mean PMC activation magnitude parameter estimates, at baseline, were negative in the control
(20.5760.12) and MCI-Nonconverter (20.3360.14) groups, and positive in the MCI-Converter (0.3760.40) and AD (0.9260.30)
groups. The effect of diagnosis on PMC deactivation remained significant after adjusting for age, education and baseline Mini-
Mental State Exam (p,0.05). Baseline PMC activation magnitude was correlated with change in dementia ratings from
baseline. Conclusion. Loss of physiological functional deactivation in the PMC may have prognostic value in preclinical AD,
and could aid in profiling subgroups of MCI subjects at greatest risk for progressive cognitive decline.
Citation: Petrella JR, Prince SE, Wang L, Hellegers C, Doraiswamy PM (2007) Prognostic Value of Posteromedial Cortex Deactivation in Mild Cognitive
Impairment. PLoS ONE 2(10): e1104. doi:10.1371/journal.pone.0001104
INTRODUCTION
Accumulating evidence suggests that synaptic dysfunction pre-
cedes neuronal death in the earliest stages of Alzheimer’s disease
(AD) [1,2,3]. Hence studies of early functional brain changes in
patients at risk for AD offer promise to compliment information
from other biomarkers such as cognitive tests, spinal fluid changes,
metabolic changes, and medial temporal volume loss [4,5,6].
Functional magnetic resonance imaging (fMRI) studies during
episodic memory encoding tasks in AD have demonstrated
decreased medial temporal activation [7,8,9,10,11,12]. However,
medial temporal lobe fMRI results in mild cognitive impairment
(MCI) have been equivocal, with some studies demonstrating
increased activation [13,14] and others decreased activation
[9,14,15,16] possibly due to sampling differences.
Theposteromedialcortex(PMC),anarchectonicallydiscretezone
comprised of the posterior cingulate, precuneus and retrosplenial
cortex, is hypothesized to be part of a network called the ‘‘default
network’’. In normal younger subjects there is functional de-
activation (decreased activation) in this network during a broad
range of cognitively challenging tasks [17]. Prior FDG PET studies
have shown that the PMC region is one of the earliest to be affected
in subjects at risk for AD [18]. Recent cross-sectional fMRI studies
have extended these findings by showing that task-related functional
PMC deactivation is reduced in AD and MCI [14,19,20]. At
baseline, there is a continuum, with normal controls demonstrating
the most efficient deactivation, AD subjects the least efficient
deactivation, and MCI subjects falling in between [21].
Although regions outside the PMC, including the frontal and
medial temporal lobes, have been implicated in previous activation
studies of MCI subjects, findings in the PMC are the strongest in
studies looking at both activation and deactivation [14,21].
Because our previous crossectional data in AD, amnestic MCI
and control subjects revealed the most robust fMRI changes in the
PMC [21], we focused on this region as the best possible predictor
of cognitive decline in amnestic MCI subjects in the present study.
To our knowledge no prior study has tested the prognostic value of
PMC deactivation in MCI.
METHODS
Subjects
The study was approved by our Institutional Review Board and
conducted in compliance with the Health Insurance Portability and
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from the local community via advertisements and referrals. All
subjects gave written informed consent prior to participation. When
appropriate, consent was also obtained from an informant and/or
legalguardianconsistentwithcurrentpracticesforADresearch[22].
A total of 98 subjects (mean age6SD=73.467.2, 49M, 49F, 20
mild AD, 44 MCI, 34 controls) were recruited and underwent fMRI
scanning.Ofthese subjects,23 (7mildAD, 10 MCI, 6 controls) were
eliminated becauseoftechnicalfactorsorinsufficientqualityoffMRI
scan data (see Exclusion Criteria), leaving 75 subjects for analysis
(mean age6SD=72.967.2, 37M, 38F, 13 mild AD, 34 MCI, 28
controls) (Table 1).
Entry Criteria
All subjects were fluent in English. Subjects underwent diagnostic
evaluations including a clinical interview and focused neurological
and mental status exam, review of medical history, demographic
inventory (age, gender, education) and brain MRI scan. Subjects
then underwent neuropsychological testing including the Califor-
nia Verbal Learning Test (CVLT) II [23], Logical Memory and
Visual Reproduction tests from the Wechsler Memory Scale
(WMS) III [24], the Mini-Mental State Exam (MMSE) [25],
a Clinical Dementia Rating (CDR)[26] interview with patient and
informant, Beck-II Depression Scale [27], and Rosen-modified
Hachinski vascular dementia rating scale [28].
Inclusion Criteria
Mild AD subjects met the following criteria: 1) a history of
progressive cognitive worsening for at least 1 year; 2) a Rosen-
modified Hachinski score of #4; 3) National Institute of Neurolog-
ical Disorders and Stroke (NINCDS-ADRDA) [29] criteria for
probable AD; 4) an MMSE score of $20, 5) a CDR global score of
1.0 (mild dementia), with a memory score of at least 1.0.
MCI (amnestic type) subjects met the following criteria: 1)
recent history of symptomatic worsening in memory; 2) a Rosen-
modified Hachinski score of #4; 3) impaired delayed recall
memory performance; 4) MMSE score of 22–30; 5) CDR global
score of 0.5, with 0.5 or greater on the memory score; 6) did not
meet NINDS or DSM-IV criteria for dementia, 7) normal or near
normal independent function; and 8) absence of other factors that
might have better explained memory loss, for example, current
major depression. These criteria were derived from prior research
[30]. Five subjects classified as MCI did not have an informant
and hence their baseline CDR score was inferred using other
information for classification purposes.
Controls met the following criteria: 1) a Rosen modified
Hachinski score of #4; 2) near normal memory performance on
delayed recall; 3) MMSE score of 25–30; 4) a CDR global score
and memory score of 0; and 5) normal independent function.
Controls did not meet NINCDS-ADRDA criteria for AD or
DSM-IV criteria for dementia and were judged to have normal
cognition.
Exclusion Criteria
Subjects were excluded on the basis of the following criteria: 1)
uncontrolled depression or other significant psychiatric or
neurological illness such as recent stroke, 2) taking psychoactive
medications known to substantially affect memory, 3) standard
contraindications to MRI 4) technical difficulties that prevented
the completion of successful anatomical imaging or at least 2 of 3
functional MRI runs, or both, 5) excessive motion during the
functional MRI exam in excess of 5mm in any of three orthogonal
directions, determined by center of mass plots, and 6) inability to
adequately monitor subject behavioral responses while in the
scanner, evidenced by greater than 50% non-responses.
Longitudinal Follow-up
All MCI subjects who completed fMRI scans successfully were
invited to return for clinical evaluation every 6 months after
baseline until they converted to AD, or until the end of the study
period. The follow-up evaluations at each visit included informant
interviews, neuropsychological testing and CDR ratings. During
follow up, MCI subjects were reclassified as MCI-Converter or
MCI-Nonconverter based on whether they were subsequently
diagnosed with dementia. The clinical diagnosis of dementia was
triggered by change in Clinical Dementia Rating (CDR) scale
score from 0.5 to 1.0, and confirmed by physician evaluations and
neuropsychological tests. Change in CDR-SOB score was avail-
able in 27 of 34 MCI subjects (1 lost to follow-up, 5 did not have
a baseline CDR, and 1 did not have a follow-up CDR score, in the
latter two situations because of unavailability of an informant). In
subjects in whom CDR was not available, a diagnosis at start and
endpoint was made using all other clinical information. The study
period of five years allowed for only up to 3.5 years of follow-up
due to initial time for study start up and enrollment.
Imaging and Image Analysis
All subjects underwent baseline fMRI scanning at 4.0T (GE
Medical Systems, Milwaukee, WI) during encoding of novel and
familiar face-name pairs, presented in a blocked experimental
design using an MR compatible goggle system (Resonance
Technology, Northridge, CA). Sixty novel and two familiar face-
name pairs were presented in 3 runs, for 6 minutes, 50 seconds
per run. Behavioral responses were monitored with a fiber-optic
button box within the scanner, with non-responses counted as
incorrect responses. The paradigm, MR scanning parameters, and
Table 1. Demographics and summary statistics.
......................................................................
Control MCI AD
Age* 71.96 (4.94) 73.64 (8.48) 71.37 (6.80)
M/F ratio* 14/14 15/18 7/6
Education{ 16.32 (2.79) 15.03 (2.52) 12.69 (2.25)
MMSE{ 28.25 (1.40) 26.82 (1.74) 24.62 (2.43)
WMSIII Logical Memory -delayed
recall{
12.71(2.48) 9.48 (3.30) 5.07 (2.02)
WMSIII Visual Reproduction-delayed
recall{
13.36 (2.86) 9.58 (3.11) 5.31 (1.44)
Beck II Depression Inventory* 5.32 (4.57) 5.12 (3.92) 5.15 (3.87)
Hachinski Vascular Dementia Scale* 1.93 (1.11) 2.29 (1.30) 1.75 (2.00)
% Novel correct score on fMRI task{
(of 30 trials)
0.71 (0.15) 0.58 (0.18) 0.46 (0.09)
% Familiar correct score on fMRI
task{ (of 30 trials)
0.96 (0.08) 0.89 (0.17) 0.80 (0.18)
% Novel and familiar correct score
on fMRI task{
0.84 (0.10) 0.74 (0.15) 0.63 (0.12)
% Non-recorded responses (of 60
trials){
0.02 (0.02) 0.06 (0.09) 0.12 (0.16)
*=NS,
{=p,0.05,
{=p,0.001
Gender tested via Chi square, other categories tested via ANOVA
Unless otherwise noted, means (SD) are listed.
doi:10.1371/journal.pone.0001104.t001
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PLoS ONE | www.plosone.org 2 October 2007 | Issue 10 | e1104individual subject image analysis are described in greater detail in
previous reports [15,21]. Briefly, anatomic and functional scans
were acquired over the same 44 continuous slice locations in the
coronal plane with the functional images measuring 3.75-mm-
thick and consisting of a time series of 164 T2*-weighted isotropic
image volumes (inverse spiral echo-planar imaging [EPI];
repetition time [TR] 2500 ms; echo time [TE] 31 ms; flip angle
[FA] 60u; matrix 64664; field of view [FOV] 240 mm). Images
were processed using Statistical Parametric Mapping (SPM2)
software [31]. The functional time series underwent slice timing
correction, spatial smoothing, global intensity scaling, and
normalization to a standardized brain template. The magnitude
of blood-oxygen-level-dependent (BOLD) signal changes were
assessed on a voxelwise basis using a general linear model
approach. A contrast map was created for each subject, depicting
mean signal magnitude change between the novel and familiar
encoding conditions across the entire brain.
An apriori, hypothesis-driven functional region of interest
(fROI) was chosen on the basis of prior data [21] demonstrating
significant cross-sectional differences in activation from healthy
elderly controls to AD subjects. This fROI was located in the
posteromedial cortical (PMC) region (Fig 1), which is defined as
the precuneus, posterior cingulate, and retrosplenial cortices. This
fROI was then applied to the contrast maps of each individual
subject, and the mean activation magnitude parameter estimate in
the PMC was determined.
Statistics
Statistical analysis was performed with SPSS software (version
12.2, 2004, SPSS Inc., Chicago, IL). For each group, summary
statistics were generated for demographic and behavioral vari-
ables, as well as performance on fMRI task (percentage correct
novel and familiar trials), and number of non-recorded responses.
An analysis of variance (ANOVA) was performed for all
continuous variables, and a chi-squared analysis was performed
for gender.
For statistical analysis of the imaging data, subjects were
classified into the following four groups, as specified above: mild
AD, MCI-Converter, MCI-Nonconverter, and controls. Activa-
tion in the PMC was considered both a nominal and continuous
variable. For treatment as a nominal variable, the category
‘‘deactivator’’ was used to denote an activation magnitude less that
zero, and ‘‘activator’’ was used to denote activation magnitude
greater than or equal to zero [19,32]. A logistic regression model
was applied using activator/deactivator status as the dependent
variable, and group as an ordinal independent variable, with age,
education and MMSE score as covariates. For treatment as
a continuous variable, an analysis of covariance (ANCOVA)
model was applied using mean activation magnitude parameter
estimate in the PMC as the dependent variable, and group as an
independent variable, with age, education and MMSE score as
covariates, and Fisher’s post hoc testing. Change in cognitive
status was also examined as a continuous variable in the MCI
subjects, using change in CDR-SOB (sum of boxes) score and
change in MMSE score. These were calculated by subtracting the
baseline score from the most recently available score. Separate
Pearson correlations were performed using mean activation in the
PMC as the dependent variable, and change in CDR-SOB score,
and change in MMSE score as the independent variables. A p-
value of ,0.05 was considered statistically significant. ANCOVA
and logistic regression analyses were also performed after adjusting
for behavioral performance on the fMRI task using novel correct
and familiar correct measures.
RESULTS
Demographics and Behavioral Variables
Demographics and behavioral test scores with summary statistics
for the 75 subjects are given in Table 1. Age, gender, depression
inventory and ischemia rating scale scores were not significantly
different among groups, however as expected, years of education,
MMSE and memory scores were significantly different among
groups.
Longitudinal Clinical Follow-up
The mean clinical follow-up for MCI subjects was 2.50 (0.79)
years. Eleven (33%) converted during the study period with mean
time-to-conversion of 2.46 (0.70) years. For the nonconverters,
mean follow-up time was 2.52 (0.84) years. There was no
statistically significant difference between mean time to conversion
in MCI-Converters and mean follow-up time in MCI-Noncon-
verters (p=0.84) over the course of this 5-year study.
PMC Deactivation
Logistic regression demonstrated that the proportion of deactiva-
tors was significantly different (p,0.05) across diagnostic groups
after adjusting for age, education and baseline MMSE score:
controls (79%), MCI-Nonconverters (73%), MCI-converters
(45%), and AD (23%), with significantly fewer deactivators with
increasing cognitive impairment grouping (Figure 2). The main
effects of age, education and baseline MMSE score were not
significant in the model.
Mean (SD) PMC regression coefficient activation magnitude for
all four groups revealed a continuum from Controls, to MCI-
Nonconverters, to MCI-Converters, to AD with negative magni-
tude in the Control and MCI-Nonconverter groups, and positive
activation magnitude in the MCI-Converter and AD groups:
Figure 1. Posteromedical cortex (PMC), denoted in red and overlaid
on a canonical T1-weighted brain template image in three
orthogonal views, was used as an apriori functional region of
interest. In this region parameter estimates for activation magnitude
showed a lesser-to-greater activation from Control, to MCI, to AD
subjects.
doi:10.1371/journal.pone.0001104.g001
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converters 0.37 (0.40), and AD 0.92 (0.30) (Figure 3). The
ANCOVA revealed a significant group main effect, independent
of age, education and MMSE score (p,0.05). The main effects of
the latter three variables were not significant in the ANCOVA
model. ANOVA post hoc testing revealed significant differences
between all groups, except the AD and MCI-Converters, and
Controls and MCI-Nonconverters. The correlation between PMC
activation magnitude and change in CDR-SOB score was 0.38
(p,0.05), and change in MMSE score 0.44 (p,0.05) (Figure 4).
ANCOVA and logistic regression analyses after adjusting for
behavioral performance remained significant (p,0.05).
DISCUSSION
While most fMRI studies in dementia have focused on positive
activations, or increases in task-related signal, recent studies in AD
have examined task-related deactivations, defined as a decrease in
signalduring anactivevs. passivetask.Previous cross-sectional fMRI
studies in AD and MCI subjects examined deactivation in the PMC
region during memory encoding tasks [19,20,21]. Using a word
encoding task in 23 AD subjects, 32 young, and 27 older controls,
Lustig et al. first demonstrated loss of deactivation in the medial
parietal/posterior cingulate region in AD and elderly control
subjects, compared to young subjects, with positive activations in
the AD group [19]. Moreover, using an exploratory approach,
Lustig et al. showed the PMC region to be the site of the largest
groups differences between AD and elderly controls found
throughout the brain. Rombouts et al. furthered these findings in
a study of 28 MCI subjects, 18 subjects with AD and 41 elderly
controls [20]. They demonstrated deactivation in the PMC in the
elderly control group during a face encoding task. MCI subjects
showed smaller regions of deactivation in the PMC and medial
frontal cortex, compared to controls and larger regions compared to
AD subjects. Petrella et al. confirmed and furthered these findings,
by demonstrating a correlation between cognitive performance and
PMC activation magnitude across the spectrum of AD, MCI and
elderly control subjects [21]. These findings prompted us to examine
the prognostic significance of deactivation in this region.
The following findings emerged from our study: 1) MCI subjects
who convert to AD have impaired PMC deactivation compared to
those who do not convert, independent of age, education and
Figure 2. Bar graph demonstrates the proportion of activators and deactivators among the four diagnostic groups. The proportion of
deactivators was significantly different (p,0.05) across diagnostic groups after adjusting for age, education and baseline MMSE score, with
significantly fewer deactivators with increasing cognitive impairment grouping.
doi:10.1371/journal.pone.0001104.g002
Figure 3. Bar graph demonstrates activation magnitude parameter
estimate in the PMC region (taken from Figure 1), demonstrating
a continuum from control, to MCI-Nonconverter, to MCI-Converter,
to AD. There were statistically significant (p,0.05) differences between
all groups with the exception of the control and MCI-Nonconverter
group, and the AD and MCI-Converter group. Note the overall pattern
of negative activation magnitude in the Control and MCI-Nonconverter
groups, and positive activation magnitude in the AD and MCI-Converter
groups.
doi:10.1371/journal.pone.0001104.g003
Mild Cognitive Impairment
PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e1104baseline MMSE score. Baseline PMC deactivation also correlates
with change from baseline in CDR-SOB; 2) Group membership,
and therefore disease status, is a more robust predictor of PMC
deactivation than age, education or MMSE score; 3) PMC
activation differences appear opposite in sign, with MCI-
nonconverter group demonstrating negative mean activation (or
deactivation), and MCI-converter subjects demonstrating loss of
deactivation (or positive activation). These levels of deactivation sit
on a continuum with AD subjects and controls at the extremes.
The mechanism underlying our findings and those of other
groups, implicating the PMC region in memory impairment, is not
completely understood. This region is one of the first to
demonstrate early hypometabolic changes in young asymptomatic
subjects in their twenties and thirties who are positive for the
apolipoprotein E4 allele, and are therefore at increased risk for
developing AD [18]. The PMC region is also part of a cortical
network revealing negative activations on PET and fMRI during
a wide variety of tasks, and has been implicated in default-mode
processing, supporting higher activity during passive vs. active
tasks [33,34]. EEG studies have demonstrated a similar network of
regions with common spontaneous power fluctuations [33,35], and
functional connectivity fMRI studies have shown high temporal
correlations in BOLD signal across these regions, implying
a functional connection [36]. While fMRI, EEG, and PET data
suggest medial parietal/posterior cingulate cortex involvement in
early AD, it is not known if this is a primary event or a secondary
consequence of MTL pathology, such as neurofibrillary tangle
deposition, which occurs early on in the disease [37]. Indeed, in
vivo human studies using the amyloid-binding radiotracer, C11
Pittsburgh Compound-B, have demonstrated a correlation in the
posterior cortical regions between amyloid deposition, atrophy and
hypometabolism, suggesting a network which is directly disrupted
in early-stage AD [38]. On the other hand, MTL regions, in
particular the entorhinal and perirhinal cortex, are densely
interconnected to the posterior cingulate cortex, and their
disruption leads to medial parietal/posterior cingulate functional
metabolic changes in both animals and humans [39,40,41,42].
Thus, it is also logical to hypothesize that AD-related loss of
deactivation in PMC regions may potentially result from structural
or functional disconnection, or both, between the PMC and MTL.
This notion is strongly supported by studies with fMRI, DTI and
EEG showing that a functional and structural disconnection
between specific memory regions, including the PMC and medial
temporal lobe, may occur in early AD [43,44,45,46,47].
MCI subjects are a heterogenous group, with some subjects
undergoing progressive cognitive decline, and others remaining
stable over time. The estimated annual conversion rate to AD in
subjects with MCI is 10–15%. Few studies have looked at the
prognostic significance of fMRI in patients with MCI. One study,
by Dickerson et al., followed 32 MCI subjects over a 2.5 year
clinical follow-up and found differences in extent of activation, at
a given statistical threshold, in the right parahippocampal gyrus, in
subjects who subsequently underwent cognitive decline, compared
to those who remained stable [48]. The authors speculate that
higher levels of activation in the medial temporal lobe are
a compensatory adaptation to less efficient neuronal activity, due
to underlying medial temporal pathology. The decliner group had
worse cognitive scores compared to the stable group at baseline,
and therefore might be demonstrating the effects of inefficient
medial temporal lobe function. Subsequent findings of the same
group demonstrate increased levels of hippocampal activation in
MCI subjects compared to normal aging and AD [13]. The
authors speculated that there is a phase of increased medial
temporal lobe activation early in the course of prodromal AD
followed by a subsequent decrease as the disease progresses. If this
is the case, then single measures of medial temporal lobe activation
alone would be problematic as a marker of disease activity,
because there would be a period of pseudonormalization of
activation that would be difficult to distinguish from normal
activation.
Our study differs from this one in several respects. First, we
looked at the magnitude of the fMRI response, as opposed to the
extent of activation. The latter measurement is dependent upon an
arbitrarily chosen statistical threshold, as well as on the length of
the fMRI experiment and underlying noise in the signal. These
results may therefore be difficult to reproduce in a different
scanner, or using a different statistical threshold. The authors also
examined differences in activation magnitude between decliners
and stable MCI subjects, yet no differences were found using this
index of activation. Second, in the study by Dickerson et al., MCI
subjects had subjective, rather than objective memory impairment
defined by cognitive testing, as opposed to our study in which
Figure 4. Scatterplots demonstrate activation magnitude parameter estimate in the PMC region (on the y-axis) significantly (p,0.05) correlated
with longitudinal change in cognitive measures (increase in CDR-SOB, decrease in MMSE) in the MCI group.
doi:10.1371/journal.pone.0001104.g004
Mild Cognitive Impairment
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is a significant difference in the samples between the two studies.
Third, ‘‘Decline’’ was defined as an increase in CDR-SOB score
by at least one point, rather than conversion to AD, as was the case
in our study. We believe the latter is a more significant clinical
endpoint.
There are a number of potential methodological biases that
could have affected our results. For example, it has been reported
in other studies that in medial parietal and frontal regions there is
an early increase in activation, followed by a rapid decrease, in
controls and MCI, but not AD subjects [19,20]. Though we did
not specifically study the temporal profile of activity in the PMC,
we did incorporate a temporal derivative of the hemodynamic
response function into our model as a covariate, and therefore
believe that our measures of activation magnitude are not biased
by differences in temporal shifts of the hemodynamic response
function. While age may also have an effect on the shape of the
hemodynamic response function [49], our MCI groups were not
significantly different in age; nevertheless, to address this concern,
we included age as a covariate in our ANCOVA model, and found
no main effect. Lastly, variable performance on cognitive tasks has
been shown to impact measured fMRI activation levels [50].
Unfortunately performance on relevant cognitive tasks tends to be
inseparable from disease status and it is impossible to completely
disentangle the two. To address this consideration, we ran analyses
to control for differences in behavioral performance during the
fMRI task across groups. Results of both ANCOVA and logistic
regression analyses still demonstrated statistically significant effects
of group membership, independent of behavioral performance.
Again, ANOVA post hoc testing revealed a significant difference
between MCI-Converter and MCI-Nonconverter groups, suggest-
ing the prognostic value of fMRI activation, independent of task
performance.
In conclusion, we have demonstrated the prognostic significance
of deactivation in the PMC region, as measured by fMRI, in
predicting future cognitive decline in patients with amnestic MCI.
As new therapeutics for prevention and treatment of AD emerge
in the coming years, fMRI may serve as an important early
diagnostic and prognostic tool, along with clinical, laboratory and
structural imaging measures, to identify at-risk candidates who
may benefit from early intervention.
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